You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 81 - 90 of 207728 results
  1. A conversational agent to support remote care for individuals with substance use disorder

    SBC: DIMAGI, INC.            Topic: NIDA

    PROJECT SUMMARY Substance use disorder (SUD) is a significant public health challenge, and it has been estimated that its effects on healthcare, work productivity, and criminal justice costs the US over $600 billion annually. Engagement with the clinical care team is critical to an individual’s path to SUD recovery; however, limited capacity of and access to addiction treatment providers and tra ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in at-risk Older Adults

    SBC: MOAI TECHNOLOGIES, LLC            Topic: NIA

    Project Summary/Abstract Alzheimer’s disease (AD) affects more than six million Americans currently and is projected to affect 14 million at a cost of $1.2 trillion in 2050. Despite its tremendous impacts and the limited influence of pharmacological therapies, attention has been brought to non-pharmacological interventions as promising therapeutic strategies for the prevention of cognitive decli ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Pharmaceutical development of longer-lasting brimonidine eye drops

    SBC: Novus Vision LLC            Topic: NEI

    PROJECT SUMMARY Glaucoma is the leading cause of irreversible blindness, impacting 80 million people worldwide. The only proven approach to prevent vision loss in glaucoma is the reduction of intraocular pressure (IOP), which is most commonly achieved by topical medications. Once daily (QD) prostaglandins are a typical first-line therapy, though the need for adjunctive therapy with other drug clas ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Medical Device Identifier to Improve Emergency Triage

    SBC: BRIDGESOURCE MEDICAL, CORP.            Topic: R

    Project Summary Abstract Cardiovascular Implantable Electronic Devices (CIEDs) like a Permanent Pacemaker or Implantable Defibrillator are implanted in over 3 million Americans, with the average age of implantation in the 60s, 40% ≥ 70 years old, and 28% ≥ 80 years old. When a patient presents to the Emergency Department (ED) with an unknown CIED, reprogramming of the device is often necessary ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. A single dose anti-scarring therapeutic for the cornea

    SBC: DUB BIOLOGICS, INC            Topic: NEI

    Abstract DUB Biologics is developing a therapeutic for the prevention and treatment of corneal scarring through knockdown of a novel target that has been shown to be central to the fibrotic response leading to corneal opacification. Corneal opacification severely impairs the vision of 4.2 million people around the world, 5.1% of the total blind population. Monocular scarring is far more common, af ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel, Low-Cost Device to Guide Peripherally Inserted Central Catheter (PICC) Line Placement

    SBC: PICCOLO MEDICAL, INC.            Topic: NIA

    Abstract In the United States alone, more than three million peripherally inserted central catheters (PICCs) are placed each year to provide IV therapies, where in about half of cases navigation through the venous system is typically performed blind, or without navigation guidance. Improper PICC placement is relatively common, is costly, and has serious complications for critically-ill patients. U ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Clustered home assessment of visual fields in patients with glaucoma

    SBC: Vivid Vision, Inc.            Topic: NEI

    Project summary/abstractGlaucoma is the second leading cause of irreversible vision loss in Americans. Effective treatment requires the patient to take visual field tests over time, to monitor for progression of visual field loss. In many patients there is no progression, but when it occurs it must be detected as quickly as possible in order to save vision by using a more aggressive treatment. Pat ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. A Digital Serious Illness Conversation Coach

    SBC: DIMAGI, INC.            Topic: NIA

    PROJECT SUMMARY It has been shown that conversations on end-of-life care focused on a patient’s goals of care can reduce psychological distress and anxiety and lead to improved quality of life, and potentially prolonged life, for patients living with serious illness. The Serious Illness Conversation Guide (SICG) is a validated and widely used framework for training the critical communication ski ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Determination of Route of Administration and Cardiac Safety of a Novel Psychoplastogen for the treatment of SUDs

    SBC: DELIX THERAPEUTICS INC            Topic: NIDA

    ABSTRACT Delix Therapeutics is developing psychoplastogens, compounds that promote rapid and sustained neuroplasticity. This new class of compounds was identified by Delix founder, Professor David Olson (UC Davis). DLX-007 is a novel, potent psychoplastogen designed and inspired by known psychoplastogens Ibogaine and 5-MeO-DMT. Similar to these clinically effective compounds, DLX-007 promotes stru ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Validation of artificial intelligence (AI) based software as medical device (SaMD) for retinopathy of prematurity (ROP)

    SBC: Siloam Vision, Inc.            Topic: NEI

    The purpose of this application is to perform the necessary clinical studies to seek regulatory approval for an artificial intelligence (AI) software as medical device (SaMD) for retinopathy of prematurity (ROP) diagnosis. ROP is a leading cause of childhood blindness worldwide, with approximately 50,000 babies going blind annually, most of which is preventable with accurate and timely diagnosis. ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government